The global market for Neurodegenerative Diseases Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Diseases Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Diseases Therapeutics.

The Neurodegenerative Diseases Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Diseases Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neurodegenerative Diseases Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neurodegenerative Diseases Therapeutics Market Report

Report Metric	Details
Report Name	Neurodegenerative Diseases Therapeutics Market
CAGR	5%
Segment by Type	Multiple Sclerosis Therapeutics Alzheimer's Disease Therapeutics Parkinson's Disease Therapeutics Others
Segment by Application	Child Aldult
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., Biogen Inc., F. Hoffmann La Roche Ltd., H Lundbeck AS, Mitsubishi Chemical Holdings Corp., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Diseases Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neurodegenerative Diseases Therapeutics Market report?

Ans: The main players in the Neurodegenerative Diseases Therapeutics Market are AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., Biogen Inc., F. Hoffmann La Roche Ltd., H Lundbeck AS, Mitsubishi Chemical Holdings Corp., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd

What are the Application segmentation covered in the Neurodegenerative Diseases Therapeutics Market report?

Ans: The Applications covered in the Neurodegenerative Diseases Therapeutics Market report are Child, Aldult

What are the Type segmentation covered in the Neurodegenerative Diseases Therapeutics Market report?

Ans: The Types covered in the Neurodegenerative Diseases Therapeutics Market report are Multiple Sclerosis Therapeutics, Alzheimer's Disease Therapeutics, Parkinson's Disease Therapeutics, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Multiple Sclerosis Therapeutics

1.2.3 Alzheimer's Disease Therapeutics

1.2.4 Parkinson's Disease Therapeutics

1.2.5 Parkinson's Disease Therapeutics

1.2.6 Others

1.3 Market by Application

1.3.1 Global Neurodegenerative Diseases Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Child

1.3.3 Aldult

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neurodegenerative Diseases Therapeutics Market Perspective (2020-2031)

2.2 Global Neurodegenerative Diseases Therapeutics Growth Trends by Region

2.2.1 Global Neurodegenerative Diseases Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Neurodegenerative Diseases Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Neurodegenerative Diseases Therapeutics Market Dynamics

2.3.1 Neurodegenerative Diseases Therapeutics Industry Trends

2.3.2 Neurodegenerative Diseases Therapeutics Market Drivers

2.3.3 Neurodegenerative Diseases Therapeutics Market Challenges

2.3.4 Neurodegenerative Diseases Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue

3.1.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Neurodegenerative Diseases Therapeutics Revenue

3.4 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio

3.4.1 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Therapeutics Revenue in 2024

3.5 Global Key Players of Neurodegenerative Diseases Therapeutics Head office and Area Served

3.6 Global Key Players of Neurodegenerative Diseases Therapeutics, Product and Application

3.7 Global Key Players of Neurodegenerative Diseases Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Diseases Therapeutics Breakdown Data by Type

4.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2026-2031)

5 Neurodegenerative Diseases Therapeutics Breakdown Data by Application

5.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Neurodegenerative Diseases Therapeutics Market Size (2020-2031)

6.2 North America Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)

6.4 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neurodegenerative Diseases Therapeutics Market Size (2020-2031)

7.2 Europe Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)

7.4 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neurodegenerative Diseases Therapeutics Market Size (2020-2031)

9.2 Latin America Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AB Science SA

11.1.1 AB Science SA Company Details

11.1.2 AB Science SA Business Overview

11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction

11.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.1.5 AB Science SA Recent Development

11.2 AbbVie Inc.

11.2.1 AbbVie Inc. Company Details

11.2.2 AbbVie Inc. Business Overview

11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction

11.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.2.5 AbbVie Inc. Recent Development

11.3 Acadia Pharmaceuticals Inc.

11.3.1 Acadia Pharmaceuticals Inc. Company Details

11.3.2 Acadia Pharmaceuticals Inc. Business Overview

11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction

11.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.3.5 Acadia Pharmaceuticals Inc. Recent Development

11.4 Biogen Inc.

11.4.1 Biogen Inc. Company Details

11.4.2 Biogen Inc. Business Overview

11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction

11.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.4.5 Biogen Inc. Recent Development

11.5 F. Hoffmann La Roche Ltd.

11.5.1 F. Hoffmann La Roche Ltd. Company Details

11.5.2 F. Hoffmann La Roche Ltd. Business Overview

11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction

11.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.5.5 F. Hoffmann La Roche Ltd. Recent Development

11.6 H Lundbeck AS

11.6.1 H Lundbeck AS Company Details

11.6.2 H Lundbeck AS Business Overview

11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction

11.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.6.5 H Lundbeck AS Recent Development

11.7 Mitsubishi Chemical Holdings Corp.

11.7.1 Mitsubishi Chemical Holdings Corp. Company Details

11.7.2 Mitsubishi Chemical Holdings Corp. Business Overview

11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction

11.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.7.5 Mitsubishi Chemical Holdings Corp. Recent Development

11.8 Novartis AG

11.8.1 Novartis AG Company Details

11.8.2 Novartis AG Business Overview

11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction

11.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.8.5 Novartis AG Recent Development

11.9 Sanofi

11.9.1 Sanofi Company Details

11.9.2 Sanofi Business Overview

11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction

11.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.9.5 Sanofi Recent Development

11.10 Teva Pharmaceutical Industries Ltd

11.10.1 Teva Pharmaceutical Industries Ltd Company Details

11.10.2 Teva Pharmaceutical Industries Ltd Business Overview

11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction

11.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)

11.10.5 Teva Pharmaceutical Industries Ltd Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

AB Science SA

AbbVie

ACADIA Pharmaceuticals Inc.

Biogen

F Hoffmann La Roche Ltd

H. Lundbeck AS

Mitsubishi Chemical Holdings Corp.

Novartis

Sanofi

Teva Pharmaceutical Industries Ltd

List of Tables

Table 1. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Multiple Sclerosis Therapeutics

Table 3. Key Players of Alzheimer's Disease Therapeutics

Table 4. Key Players of Parkinson's Disease Therapeutics

Table 5. Key Players of Parkinson's Disease Therapeutics

Table 6. Key Players of Others

Table 7. Global Neurodegenerative Diseases Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2020-2025)

Table 11. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2026-2031)

Table 13. Neurodegenerative Diseases Therapeutics Market Trends

Table 14. Neurodegenerative Diseases Therapeutics Market Drivers

Table 15. Neurodegenerative Diseases Therapeutics Market Challenges

Table 16. Neurodegenerative Diseases Therapeutics Market Restraints

Table 17. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global Neurodegenerative Diseases Therapeutics Market Share by Players (2020-2025)

Table 19. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2024)

Table 20. Ranking of Global Top Neurodegenerative Diseases Therapeutics Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of Neurodegenerative Diseases Therapeutics, Headquarters and Area Served

Table 23. Global Key Players of Neurodegenerative Diseases Therapeutics, Product and Application

Table 24. Global Key Players of Neurodegenerative Diseases Therapeutics, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2020-2025)

Table 28. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2026-2031)

Table 30. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2020-2025)

Table 32. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2026-2031)

Table 34. North America Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 49. AB Science SA Company Details

Table 50. AB Science SA Business Overview

Table 51. AB Science SA Neurodegenerative Diseases Therapeutics Product

Table 52. AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 53. AB Science SA Recent Development

Table 54. AbbVie Inc. Company Details

Table 55. AbbVie Inc. Business Overview

Table 56. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product

Table 57. AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 58. AbbVie Inc. Recent Development

Table 59. Acadia Pharmaceuticals Inc. Company Details

Table 60. Acadia Pharmaceuticals Inc. Business Overview

Table 61. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product

Table 62. Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 63. Acadia Pharmaceuticals Inc. Recent Development

Table 64. Biogen Inc. Company Details

Table 65. Biogen Inc. Business Overview

Table 66. Biogen Inc. Neurodegenerative Diseases Therapeutics Product

Table 67. Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 68. Biogen Inc. Recent Development

Table 69. F. Hoffmann La Roche Ltd. Company Details

Table 70. F. Hoffmann La Roche Ltd. Business Overview

Table 71. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product

Table 72. F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 73. F. Hoffmann La Roche Ltd. Recent Development

Table 74. H Lundbeck AS Company Details

Table 75. H Lundbeck AS Business Overview

Table 76. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product

Table 77. H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 78. H Lundbeck AS Recent Development

Table 79. Mitsubishi Chemical Holdings Corp. Company Details

Table 80. Mitsubishi Chemical Holdings Corp. Business Overview

Table 81. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product

Table 82. Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 83. Mitsubishi Chemical Holdings Corp. Recent Development

Table 84. Novartis AG Company Details

Table 85. Novartis AG Business Overview

Table 86. Novartis AG Neurodegenerative Diseases Therapeutics Product

Table 87. Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 88. Novartis AG Recent Development

Table 89. Sanofi Company Details

Table 90. Sanofi Business Overview

Table 91. Sanofi Neurodegenerative Diseases Therapeutics Product

Table 92. Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 93. Sanofi Recent Development

Table 94. Teva Pharmaceutical Industries Ltd Company Details

Table 95. Teva Pharmaceutical Industries Ltd Business Overview

Table 96. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product

Table 97. Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)

Table 98. Teva Pharmaceutical Industries Ltd Recent Development

Table 99. Research Programs/Design for This Report

Table 100. Key Data Information from Secondary Sources

Table 101. Key Data Information from Primary Sources

Table 102. Authors List of This Report

List of Figures

Figure 1. Neurodegenerative Diseases Therapeutics Picture

Figure 2. Global Neurodegenerative Diseases Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Neurodegenerative Diseases Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Multiple Sclerosis Therapeutics Features

Figure 5. Alzheimer's Disease Therapeutics Features

Figure 6. Parkinson's Disease Therapeutics Features

Figure 7. Parkinson's Disease Therapeutics Features

Figure 8. Others Features

Figure 9. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global Neurodegenerative Diseases Therapeutics Market Share by Application: 2024 VS 2031

Figure 11. Child Case Studies

Figure 12. Aldult Case Studies

Figure 13. Neurodegenerative Diseases Therapeutics Report Years Considered

Figure 14. Global Neurodegenerative Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Neurodegenerative Diseases Therapeutics Market Share by Region: 2024 VS 2031

Figure 17. Global Neurodegenerative Diseases Therapeutics Market Share by Players in 2024

Figure 18. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2024

Figure 20. North America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)

Figure 22. United States Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)

Figure 26. Germany Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Region (2020-2031)

Figure 34. China Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)

Figure 42. Mexico Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)

Figure 46. Turkey Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. AB Science SA Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 50. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 51. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 52. Biogen Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 53. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 54. H Lundbeck AS Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 55. Mitsubishi Chemical Holdings Corp. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 56. Novartis AG Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 57. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 58. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Neurologic Disorder Treatment Drug Market Research Report 2024

Neurology Digital Therapeutics Market

Central Nervous System Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Alzheimer Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drugs of Neuron Management Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Alzheimer s Therapeutic Market Research Report 2024

Alzheimer Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Alzheimer s Treatment Drug Market Research Report 2024

Global Alzheimer s Drugs Market Research Report 2025

Global Early Diagnosis Kit For Alzheimer s Disease Market Research Report 2024

Central Nervous System Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Medicines for Alzheimer Disease Treatment Market Research Report 2025

AI Assisted Diagnosis in Neurology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Tauopathies Treatment Market Research Report 2025

Global Alzheimer s Clinical Treatment Drug Market Research Report 2025

Chronic Metabolic Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Prion Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Parkinson Treatment Drug Market Research Report 2025

Multiple Sclerosis Therapies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

[email protected]

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

	
		OSZAR »